Article

Ponatinib for RAS-Driven Multiple Myeloma: Efficacy in the High-Risk VQ Myeloma Model

2022-02-21

Abstract excerpt

Multiple myeloma (MM) is a malignant plasma cell cancer. Mutations in RAS pathway genes are prevalent in advanced and proteasome inhibitor (PI) refractory MM. As such, we recently developed a VQ MM mouse model recapitulating human advanced/high-risk MM. Using VQ MM cell lines we conducted a re-purpose screen of 147 FDA-approved anti-cancer drugs with or without trametinib (Tra), a MEK inhibitor. Consistent with it...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: bc5ca452-4703-5e2a-9948-892a1b68acc3
DOI: 10.21203/rs.3.rs-1296881/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Ponatinib for RAS-Driven Multiple Myeloma: Efficacy in the High-Risk VQ Myeloma ModelDOI 10.21203/rs.3.rs-1296881/v1Read

Expression of Nras Q61R and MYC transgene in germinal center B cells induces a highly malignant multiple myeloma in miceSemantic proximity Read

Pathway-Directed Therapy in Multiple MyelomaSemantic proximity Read

Genomic and transcriptional profiling stratifies VQ myeloma lines into two clusters with distinct risk signatures and drug responsesSemantic proximity Read

Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myelomaSemantic proximity Read

Stability of c-Myc protein differentiates Ras oncogene addiction and MAPK pathway dependency in Ras-mutant multiple myelomaSemantic proximity Read

Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1Semantic proximity Read

Pan-Raf co-operates with PI3K-dependent signalling and critically contributes to myeloma cell survival independently of mutated RAS.Semantic proximity Read

Stability of c-Myc protein differentiates Ras oncogene addiction and MAPK pathway dependency in Ras-mutant multiple myelomaSemantic proximity Read

CAR T-cell therapy in multiple myeloma: mission accomplished?Semantic proximity Read

Targeting the BRAF V600E mutation in multiple myeloma.Semantic proximity Read

Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation.Semantic proximity Read

Sorafenib Has Potent Antitumor Activity against Multiple Myeloma In Vitro , Ex Vivo , and In Vivo in the 5T33MM Mouse ModelSemantic proximity Read